Biorce's $52M Boost: How AI Could Revolutionize Clinical Trials and Save Lives

The clinical trial process has long been plagued by inefficiencies, with protocol amendments and regulatory hurdles causing significant delays and added costs. However, Barcelona-based health AI company Biorce is on a mission to change this. With its recent $52 million Series A round, the company is poised to support the global rollout of its AI clinical trial platform, Aika. Aika is designed to reduce clinical trial preparation timelines and limit protocol amendments, thereby supporting faster development of new therapies.



The need for such a platform cannot be overstated. Traditional trial models often result in protocol amendments that pause patient recruitment for an average of six weeks and can add between €500,000 and €1 million in costs per amendment. These challenges are frequently linked to difficulties in clearly substantiating trial design decisions to regulatory authorities, which can lead to extended reviews, delays, and additional amendments. Biorce's CEO, Pedro Coelho, emphasized the human cost of these delays, stating that they cost time, money, and ultimately lives.



Aika is built on a dataset of approximately one million clinical trials and is designed to help anticipate risks, reduce errors, and limit the need for protocol changes. The platform supports pharmaceutical companies, biotech firms, and contract research organisations in designing trials more efficiently while maintaining scientific standards and patient safety. Aika is already in use across multiple therapeutic areas, including oncology, neurology, and rare diseases.



The implications of Biorce's platform extend beyond the pharmaceutical industry. For everyday users, this could mean faster access to life-saving treatments. From an industry perspective, Aika has the potential to reshape how clinical trials are designed and conducted, reducing costs and increasing efficiency. As Biorce plans to expand its workforce and open a development and R&D hub in Austin, Texas, the company is well-positioned to support its activities in the US and further develop Aika's protocol intelligence capabilities.



Looking ahead, the introduction of additional modules, including tools for contract management, negotiation, budget planning, and operational execution, will be crucial in improving trial efficiency and patient access to new therapies. With its recent funding and strategic plans in place, Biorce is set to make a significant impact on the clinical trial landscape.



The clinical trial process is complex and multifaceted, involving various stakeholders and regulatory bodies. Biorce's Aika platform has the potential to streamline this process, reducing the burden on pharmaceutical companies and contract research organisations. As the company continues to grow and expand its offerings, it will be interesting to see how the industry responds to this new approach.



In conclusion, Biorce's $52 million Series A round is a significant development in the clinical trial space. With its AI-powered platform, Aika, the company is poised to revolutionize the way clinical trials are designed and conducted. As the company looks to the future, it is clear that its mission to make trials faster, more reliable, and more accessible will have a profound impact on the pharmaceutical industry and beyond.